Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management. It has two products in clinical development, which include Zingo and 4975. Zingo is an anesthetic that has completed two Phase 3 trials in the pediatric population for the treatment of pain associated with venipuncture and cannulation; and 4975 is an anesthetic for the treatment of site-specific moderate to severe pain, and is in multiple Phase 2 and Phase 3 trials in post-surgical and musculoskeletal pain. The company was incorporated in 2001. It was formerly known as Corgentech, Inc. and changed its name to Anesiva, Inc. in 2006. Anesiva is headquartered in South San Francisco, California.